Drug Trial Radar · NCT07951346
N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Feb 1, 2026
Primary completion
Sep 14, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- RSUP PersahabatanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Universitas Indonesia
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred. This study aimed to find out whether oral NAC, given as an adjuvant therapy, improves liver function and nausea-vomiting in hospitalized adults with drug-susceptible TB who developed AT-DILI. Participants were randomly assigned to receive effervescent NAC 600 mg twice daily for 7 days or no NAC. Liver tests (ALT, AST, and total bilirubin) were measured on days 0, 3, 6, and 9, and nausea and vomiting were assessed daily from day 0 to day 9.
Conditions
- Drug-Induced Liver Injury
- Tuberculosis
Interventions
N-acetylcysteine (NAC)Drug
Effervescent N-acetylcysteine 600 mg tablet, taken orally twice daily (2 × 600 mg) for 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Alanine Aminotransferase (ALT/SGPT)Time frame: Baseline (day 0), day 3, day 6, and day 9
- Change in Serum Aspartate Aminotransferase (AST/SGOT)Time frame: Baseline (day 0), day 3, day 6, and day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Persahabatan National Respiratory Referral Hospital
Jakarta, DKI Jakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.